Literature DB >> 24510830

Low-energy DC current ablation in a mouse tumor model.

Prejesh Philips1, Yan Li, Robert C G Martin.   

Abstract

Irreversible electroporation has recently been applied to tissue and tumor ablation. This animal model was developed to evaluate optimal parameters for subcutaneous tumor ablation. The immortalized Panc1 tumor cell line was used for generating tumors via subcutaneous injection in mice. Under general anesthesia with complete muscle relaxation, electroporation was performed with the NanoKnife device. Post-procedure tumors were recovered and studied at specified time intervals to assess the efficacy.

Entities:  

Mesh:

Year:  2014        PMID: 24510830     DOI: 10.1007/978-1-4614-9632-8_23

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  4 in total

1.  An update on the role of irreversible electroporation in locally advanced pancreatic adenocarcinoma.

Authors:  Robert C G Martin
Journal:  HPB (Oxford)       Date:  2016-08-16       Impact factor: 3.647

2.  Efficacy of irreversible electroporation in human pancreatic adenocarcinoma: advanced murine model.

Authors:  Prejesh Philips; Yan Li; Suping Li; Charles R St Hill; Robert Cg Martin
Journal:  Mol Ther Methods Clin Dev       Date:  2015-03-04       Impact factor: 6.698

3.  Optimizing Patient Selection for Irreversible Electroporation of Locally Advanced Pancreatic Cancer: Analyses of Survival.

Authors:  Matthew R Woeste; Khaleel D Wilson; Edward J Kruse; Matthew J Weiss; John D Christein; Rebekah R White; Robert C G Martin
Journal:  Front Oncol       Date:  2022-01-13       Impact factor: 6.244

Review 4.  Electrochemotherapy in pancreatic adenocarcinoma treatment: pre-clinical and clinical studies.

Authors:  Sabrina Bimonte; Maddalena Leongito; Vincenza Granata; Antonio Barbieri; Vitale Del Vecchio; Michela Falco; Aurelio Nasto; Vittorio Albino; Mauro Piccirillo; Raffaele Palaia; Alfonso Amore; Raimondo di Giacomo; Secondo Lastoria; Sergio Venanzio Setola; Roberta Fusco; Antonella Petrillo; Francesco Izzo
Journal:  Radiol Oncol       Date:  2016-02-16       Impact factor: 2.991

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.